Financing channel feed

Eu­ro­pean in­vestor Early­bird Health clos­es $185M fund to back 12 to 15 com­pa­nies

Last year
Startups

The End­points Slack in­ter­view: Zavain Dar on start­ing a new VC, trust­ing the process with the 76ers, and Ap­ple's VR fu­ture

Last year
People

BioAge rais­es $170M as obe­si­ty spot­light shifts to oral op­tions, mus­cle pre­servers

Last year
Startups

Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Last year
Startups
China

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Last year
Startups

Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

Last year
Startups
Cell/Gene Tx

Neu­rona rais­es $120M to take epilep­sy cell ther­a­py to late-stage de­vel­op­ment

Last year
Startups
Cell/Gene Tx

Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Last year
Startups
Cell/Gene Tx

Ex­clu­sive: With an eye to­ward ex­pan­sion, an AI com­pa­ny that sup­ports CD­MOs com­pletes $20M Se­ries C raise

Last year
Manufacturing

A new VC fund emerges with $310M to cre­ate in­de­pen­dent, com­mer­cial biotechs

Last year
Startups

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Last year
Cell/Gene Tx

ARCH, one of life sci­ences' pre­mier in­vestors, eyes $3B for 13th fund

Last year
Startups

Al­to Neu­ro­science and Fractyl Health add to biotech IPO mo­men­tum in Fri­day dou­ble­head­er

Last year
Startups

Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

Last year
Startups

Kyver­na seeks $182M IPO as biotech runs mul­ti­ple au­toim­mune CAR-T tri­als

Last year
Cell/Gene Tx

Vax­cyte prices $750M of­fer­ing, one of biotech’s largest, as it goes up against Big Phar­ma's pneu­mo­coc­cal vac­cines

Last year

Dana­her out­does low fourth-quar­ter rev­enue ex­pec­ta­tions, fore­casts slow 2024

Last year
Diagnostics

Chica­go-area au­toim­mune biotech gets phar­ma back­ing in $105M round for two PhII tri­als

Last year
Startups

Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Last year
Startups

Fractyl has the GUTS: Obe­si­ty and di­a­betes biotech charts $99M IPO

Last year
Cell/Gene Tx

Ex­clu­sive: UK biotech rais­es $33.1M to test CF drug that could work on top of stan­dard of care

Last year

In­no­va­tion En­deav­ors’ Joel Dud­ley on grow­ing in­ter­est in life sci­ences with new fund — and why he hates ‘tech­bio’

Last year
People

UK's 're­silien­t' life sci­ences sec­tor hopes for up­turn af­ter de­creas­es in fi­nanc­ing, ven­ture cap­i­tal in 2023 — re­port

Last year

Ar­riVent prices $175M IPO in back-to-back on­col­o­gy biotech list­ings

Last year
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times